196 related articles for article (PubMed ID: 2817848)
1. Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
Nicas TI; Cole CT; Preston DA; Schabel AA; Nagarajan R
Antimicrob Agents Chemother; 1989 Sep; 33(9):1477-81. PubMed ID: 2817848
[TBL] [Abstract][Full Text] [Related]
2. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
Johnson AP; Uttley AH; Woodford N; George RC
Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
Collins LA; Malanoski GJ; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Mar; 37(3):598-601. PubMed ID: 8460927
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.
Yamane N; Jones RN
Diagn Microbiol Infect Dis; 1991; 14(4):337-45. PubMed ID: 1889183
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species.
Swenson JM; Facklam RR; Thornsberry C
Antimicrob Agents Chemother; 1990 Apr; 34(4):543-9. PubMed ID: 2344161
[TBL] [Abstract][Full Text] [Related]
8. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
Collins LA; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Jun; 37(6):1364-6. PubMed ID: 8328787
[TBL] [Abstract][Full Text] [Related]
10. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
11. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of non-enterococcal intrinsic glycopeptide-resistant Gram-positive organisms.
Vay C; Cittadini R; Barberis C; Hernán Rodríguez C; Perez Martínez H; Genero F; Famiglietti A
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):183-8. PubMed ID: 17049799
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
Grüneberg RN; Hryniewicz W
Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
[TBL] [Abstract][Full Text] [Related]
14. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.
Sahm DF; Kissinger J; Gilmore MS; Murray PR; Mulder R; Solliday J; Clarke B
Antimicrob Agents Chemother; 1989 Sep; 33(9):1588-91. PubMed ID: 2554802
[TBL] [Abstract][Full Text] [Related]
16. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum.
Billot-Klein D; Gutmann L; Sablé S; Guittet E; van Heijenoort J
J Bacteriol; 1994 Apr; 176(8):2398-405. PubMed ID: 8157610
[TBL] [Abstract][Full Text] [Related]
17. [Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine].
Rudy M; Nowakowska M; Wiechuła B; Zientara M; Radosz-Komoniewska H
Przegl Lek; 2004; 61(5):473-6. PubMed ID: 15515808
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria.
de la Maza L; Ruoff KL; Ferraro MJ
Antimicrob Agents Chemother; 1989 Aug; 33(8):1383-4. PubMed ID: 2552910
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria.
Dutka-Malen S; Leclercq R; Coutant V; Duval J; Courvalin P
Antimicrob Agents Chemother; 1990 Oct; 34(10):1875-9. PubMed ID: 2291654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
